We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, ANI Pharmaceuticals (ANIP - Free Report) closed at $70.39, marking a -0.13% move from the previous day. This change lagged the S&P 500's 0.46% gain on the day. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq added 0.59%.
Coming into today, shares of the drugmaker had gained 10.99% in the past month. In that same time, the Medical sector gained 0.72%, while the S&P 500 gained 3.24%.
Wall Street will be looking for positivity from ANIP as it approaches its next earnings report date. In that report, analysts expect ANIP to post earnings of $1.03 per share. This would mark a year-over-year decline of 21.97%.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.97 per share and revenue of $248 million. These totals would mark changes of +17.75% and +23.03%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for ANIP. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.92% higher within the past month. ANIP is currently a Zacks Rank #1 (Strong Buy).
Investors should also note ANIP's current valuation metrics, including its Forward P/E ratio of 11.82. This valuation marks a discount compared to its industry's average Forward P/E of 21.03.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, ANI Pharmaceuticals (ANIP - Free Report) closed at $70.39, marking a -0.13% move from the previous day. This change lagged the S&P 500's 0.46% gain on the day. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq added 0.59%.
Coming into today, shares of the drugmaker had gained 10.99% in the past month. In that same time, the Medical sector gained 0.72%, while the S&P 500 gained 3.24%.
Wall Street will be looking for positivity from ANIP as it approaches its next earnings report date. In that report, analysts expect ANIP to post earnings of $1.03 per share. This would mark a year-over-year decline of 21.97%.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.97 per share and revenue of $248 million. These totals would mark changes of +17.75% and +23.03%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for ANIP. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.92% higher within the past month. ANIP is currently a Zacks Rank #1 (Strong Buy).
Investors should also note ANIP's current valuation metrics, including its Forward P/E ratio of 11.82. This valuation marks a discount compared to its industry's average Forward P/E of 21.03.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.